RhumbLine Advisers’s vTv Therapeutics VTVT Stock Holding History

RhumbLine Advisers’s Portfolio VTVT Stock Details VTVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-363	Closed	-$33K	–	3046
2020 Q2	$33K	Buy	+363	New	+$35.8K	﹤0.01%	3043

Other funds holding VTVT

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

RhumbLine Advisers's VTVT Position: Q3 2020 in Review

RhumbLine Advisers sold out of vTv Therapeutics (VTVT) in Q3 2020, closing a stake of 363 shares — an estimated $33K sold.

RhumbLine Advisers first reported a position in VTVT in Q2 2020 and held it in 1 quarter. The position peaked at $33K in Q2 2020. 39 funds tracked by Wall St. Rank hold VTVT as of Q3 2020.

RhumbLine Advisers reported no remaining vTv Therapeutics position as of Q3 2020 after selling out during the quarter.
RhumbLine Advisers sold 363 vTv Therapeutics shares in Q3 2020, an estimated $33K.
RhumbLine Advisers first reported a position in vTv Therapeutics in Q2 2020 and held it in 1 quarter.
RhumbLine Advisers's vTv Therapeutics position peaked at $33K in Q2 2020.
39 funds tracked by Wall St. Rank held vTv Therapeutics as of Q3 2020.

Based on RhumbLine Advisers's 13F filing for Q3 2020, filed 12 Nov 2020.